The FDA has approved FoundationOne CDx as the registrational companion diagnostic for pemigatinib (Pemazyre), which the agency recently approved for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test.
In light of the COVID-19 pandemic, transplant-eligible patients with cancer are undergoing careful assessment to determine whether they should proceed with the procedure or receive additional consolidation therapy to buy time, according to Naval G. Daver, MD.
While many providers are in favor of physician-assisted dying, others are against it, and payment may also become a barrier.
Just as the situation with COVID-19 continues to rapidly evolve, the oncology community must actively adapt how they approach the treatment of their patients based on the information available, according to Balazs Halmos, MD, MS.
Patients at risk of developing thrombosis should receive anticoagulants, in the form of Xa inhibitors and, if necessary, andexanet alfa (Andexxa) or prothrombin concentrates to control excessive bleeding, explained Alvin H. Schmaier, MD.
This is the first FDA approval for this patient population.
The FDA has approved tucatinib (Tukysa) for use in combination with trastuzumab (Herceptin) and capecitabine (Xeloda) for the treatment of patients with unresectable locally advanced or metastatic HER2-positive breast cancer, including patients with brain metastases, following at least 1 prior therapy.
Although the emergence of more targeted and immunotherapies continues to expand the melanoma treatment paradigm, surgery remains an important tool in the management of these patients, according to Omid Hamid, MD.
The COVID-19 pandemic has shocked the US healthcare system, highlighting our flaws while showing our deep commitment to quality patient care. We in healthcare cannot “pause,” but I am hoping millions of people around the world will do so and realign their convictions from the lessons learned.
Findings from the phase II FIGHT-202 study of pemigatinib in patients with previously treated, locally advanced or metastatic FGFR2-positive cholangiocarcinoma have been published in the Lancet Oncology as the FDA considers a new-drug application (NDA) for the treatment in this setting.
The FDA approved mitomycin gel (Jelmyto) for the treatment of patients with low-grade upper tract urothelial cancer (UTUC), cancer of the lining of the urinary system. This is the first therapy approved in this space.
Leading oncology and breast cancer organizations came together to create treatment recommendations for patients with breast cancer during the COVID-19 pandemic.
Acalabrutinib (Calquence), a BTK inhibitor approved for the treatment of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), is being explored in the CALAVI trial as a treatment for cytokine storm in patients with COVID-19.
The relationship between the two maladies still remains vastly unknown.
The FDA granted priority review to the new drug application for sodium thiosulfate for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to
T-cell therapies, such as tumor-infiltrating lymphocyte (TIL) therapy, T-cell receptor (TCR) therapy, and CAR T-cell therapy, which have shown preliminary signals of activity, are poised to have a dramatic impact in metastatic melanoma, according to Jason J. Luke, MD, FACP.
We want to hear from you what you think about telemedicine and in-home cancer care during the COVID-19 pandemic.
An increased proportion of Indigenous American (IA) genetic ancestry may be linked with a higher incidence of HER2-positive breast cancer, according to findings from a study published in Cancer Research.
The FDA approved selumetinib (Koselugo) to treat pediatric patients aged 2 years or older with neurofibromatosis type 1. This is the first-ever therapy approved for this rare genetic disorder, which causes tumors to grow on nerves.
Although efforts to “flatten the curve” are showing some signs of hope, the COVID-19 crisis continues to present major challenges to the oncology community.
Given our current climate, we must be intentional with our approach, starting within the admission department through the journey of the patient to the outpatient setting.
Leronlimab is an investigational humanized IgG4 monoclonal antibody that blocks CCR5, a cellular receptor that appears to play multiple roles with implications in HIV infection, tumor metastases, and immune signaling.
The FDA approved the combination use of encorafenib and cetuximab for the treatment of adult patients with BRAFV600E-positive metastatic colorectal cancer.
Bristol Myers Squibb recently announced that the FDA granted priority review to nivolumab plus ipilimumab in combination with chemotherapy as a first-line treatment for metastatic NSCLC.
The NCCN, ASCO, ASH, and CDC came together to publish an article on appropriate opioid use in cancer care.
The FDA granted priority review to pembrolizumab monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic TMB-high solid tumors who have progressed following prior treatment and who have no satisfactory alternative treatment options.
All healthcare providers are providing care to the best of their ability, but strangely it does not seem like enough.
Media coverage of COVID-19, the disease caused by the new coronavirus, has ramped up significantly in recent weeks as new cases are being reported around the country and the world.
From implementing telemedical approaches to resequencing treatments, cancer centers across the nation have nimbly adapted to face the clinical challenges posed by the novel coronavirus 2019 disease (COVID-19). These adjustments in standard operating procedures mitigate the risk for virus spread among clinicians and patients alike.
CYNK-001 will be evaluated in an upcoming phase I/II clinical trial including up to 86 patients with COVID-19.
